NCT06413459|Recruiting
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
BioMol-MA
Loading search results
BioMol-MA
Sponsor study identifier
observational
40
1 country
1
Study Start
April 8, 2021
Actual (reported)Primary Completion
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 8, 2021
Actual (reported)May 9, 2024
Actual (reported)May 14, 2024
Actual (reported)March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
profile of specific cell populations and expression markers to determine the development and progression of M. abscessus lung disease in patients with CF
Evaluate the correlation between early alterations in the profile of specific cell populations or expression markers or soluble immunity activation proteins, considering in particular the development and progression of M. abscessus lung disease in patients with cystic fibrosis
One month after enrollment visit
Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with cystic fibrosis
Ospedale San Raffaele
Milan, MI, 20132, Italy
PBMCs and Plasma
First Submitted
May 9, 2024
First Posted
May 14, 2024
Study Start
April 8, 2021
Actual (reported)Primary Completion
March 30, 2027
EstimatedEstimated Impact of Fungal Colonization in Cystic Fibrosis From Secondary Exploitation of MucoFong Database.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 16, 2024
Record last verified: 2023-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: